TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
Fireside chat scheduled for Wednesday, June 5, 2024, at 1:30 PM ET
2024年6月5日星期三东部时间下午1:30举行交流会
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 5-6, 2024. The fireside chat is scheduled to take place on Wednesday, June 5, 2024, at 1:30 PM ET.
纽约，2024年6月3日，全球新闻发稿——TG Therapeutics，Inc.（纳斯达克：TGTX）今天宣布，该公司的董事长兼首席执行官Michael S. Weiss将参加Jefferies全球医疗保健大会，该大会于2024年6月5-6日在纽约市万豪酒店举行，交流会定于2024年6月5日星期三东部时间下午1:30举行。
A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company's website at http://ir.tgtherapeutics.com/events.
交流会的现场网络直播将在该公司网站的投资者和媒体部分的活动页面（http://ir.tgtherapeutics.com/events）提供。关于TG THERAPEUTICS.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
TG Therapeutics是一家完全集成、商业化阶段的生物制药公司，专注于收购、开发和商业化B细胞疾病的新型治疗方法。除了研究管线中包含几种调查药物外，TG还获得了美国食品和药品管理局的批准，使用BRIUMVI（ublituximab-xiiy）治疗复发性多发性硬化症的成人患者（RMS），包括临床分离综合征、复发缓解性疾病和活动性继发性疾病，以及欧洲委员会（EC）和药品和医疗保健产品监管局（MHRA）批准BRIUMVI用于治疗欧洲和英国分别具有临床或成像特征的RMS成人患者的活动性疾病。有关详细信息，请访问www.tgtherapeutics.com，并在X（前称Twitter）@TGTherapeutics上关注我们，并在
BRIUMVI是TG Therapeutics，Inc.的注册商标。LinkedIn.
BRIUMVI is a registered trademark of TG Therapeutics, Inc.
BRIUMVI是tg therapeutics注册商标。
CONTACT:
联系人：
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
投资者关系
电子邮件: ir@tgtxinc.com
电话：1.877.575.TGTX（8489），选项4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
媒体关系：
电子邮件: media@tgtxinc.com
电话：1.877.575.TGTX（8489），选项6